OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Cystic Fibrosis is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Worldwide rates of diagnosis and effective treatment for cystic fibrosis	109
A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis	100
Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease	95
The global impact of SARS-CoV-2 in 181 people with cystic fibrosis	71
Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID)	62
Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis	62
Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection	60
Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials	59
Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators – an international survey	57
Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study	57
Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis–data from the European cystic fibrosis society patient registry	56
Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR	52
Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action	51
Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation	50
Cystic fibrosis related diabetes in Europe: Prevalence, risk factors and outcome; Olesen et al	49
Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis	46
Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Atalur	45
New approaches to genetic therapies for cystic fibrosis	45
Investigating transmission of Mycobacterium abscessus amongst children in an Australian cystic fibrosis centre	44
Effect of one-year lumacaftor–ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients	44
Modeling pulmonary cystic fibrosis in a human lung airway-on-a-chip	43
Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy	43
Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids	43
Development of the gut microbiota in early life: The impact of cystic fibrosis and antibiotic treatment	41
Patient and family perceptions of telehealth as part of the cystic fibrosis care model during COVID-19	41

Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series	41
Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis	41
The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis	40
Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients	39
Integrating the multiple breath washout test into international multicentre trials	38
PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy	38
Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis	37
Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis	37
Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis	36
The impact of the COVID-19 pandemic on the emotional well-being and home treatment of Belgian patients with cystic fibrosis, including transplanted patients and paediatric patients	35
Amplifiers co-translationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA	35
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous	35